Eli Lilly and Company has launched its insulin glargine biosimilar, Rezvoglar (insulin glargine-aglr), on the US market, making it the second interchangeable insulin biosimilar to become commercially available to American patients with diabetes.
Eli Lilly and Company has launched its insulin glargine biosimilar, Rezvoglar (insulin glargine-aglr), on the US market, making it the second interchangeable insulin biosimilar to become commercially available to American patients with diabetes.
Lilly’s KwikPen autoinjector for Rezvoglar
Rezvolgar was approved as the fourth biosimilar to receive an interchangeability designation in November 2022. It was originally approved by the FDA in December 2021. Insulin glargine products are used to improve glycemic control in adult and pediatric patients with type 1 diabetes and in adults with type 2 diabetes.
Interchangeability allows for pharmacists to substitute an insulin glargine prescription with Rezvoglar or Semglee (insulin glargine-yfgn), the first insulin glargine biosimilar to be deemed interchangeable, without having to get permission from a physician. The designation is unique to the United States and is intended to improve accessibility to biosimilars by allowing patients to get their medications faster if the one listed on their prescription is not available.
In early March, when Lilly announced that it will lower its list prices for all its insulin products, the company disclosed that Rezvolgar will launch at a 78% discount to the reference product (Lantus). The biosimilar will be available to patients for $92 for a 5-pack of KwikPens, the company’s autoinjector device.
In addition to Semglee and Lantus, Rezvoglar will compete against Basaglar, an authorized generic insulin. Authorized generic products, also known as follow-on biologics, are biosimilars by definition; however, because they were approved by the FDA prior to the installation of a biosimilars approval pathway, they are not legally considered biosimilars in the United States.
Outside of Rezvoglar, Lilly is the owner of Humulin (recombinant human insulin) and Humalog (reference insulin lispro), as well as an unbranded insulin lispro product.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Review Finds 7 Themes That Can Help Define the Value of Biosimilars
June 10th 2024Authors of an integrated literature review identified 7 themes that help stakeholders define the value of biosimilar portfolios beyond cost savings, which could provide stakeholders better clarity as to the value of a biosimilar portfolio vs a single biosimilar within a portfolio.